


In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please amend claims 1, 2, 10, 17, and 18 as follows.

1. (currently amended) A compound of formula I



I

wherein

R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO₂C₁₋₄alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄ alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R³ represents H or a C₁₋₄ alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl $(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4 , respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O or, alternatively, the group $-N(R^3)-L^1$ or the group $L^1-N(R^4)$ together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively;~~

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl; ~~or L^2 may also represent a 5-6 membered carbocyclic ring fused to R^5 ;~~

R^5 represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinoliny, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridinyl, 5*H*-pyrrolo[2,3-*b*]pyrazinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*b*]pyridinyl, 1*H*-indazolyl, 1*H*-pyrrolo[3,2-*h*]quinoliny, 1*H*-pyrrolo[3,2-*b*]pyridinyl, 2,1,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinazoliny or triazolyl wherein each R^5 is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $O_x(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4} alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with the proviso that when

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro or a

C₁₋₄alkyl group optionally substituted by one or more fluoro; and

n represents 0 or 1; and

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a

C₁₋₄alkoxy group optionally substituted by one or more fluoro; and

m represents 0 or 1; and

R³ represents H or a C₁₋₄alkyl group; and

L¹ represents a cyclohexyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L¹ represents a cyclopentyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group; and

L² represents an alkylene chain (CH₂)_s in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C₁₋₄alkyl group; and

R⁵ represents aryl wherein aryl means phenyl or naphthyl each of which is optionally substituted by one or more of the following: halo, a C₁₋₄alkyl group or phenyl, or


R⁵ represents a heterocyclic group wherein the term heterocyclic group means thienyl, furyl, pyridyl, pyrrolyl, quinoliny, indolyl, benzofuranyl or benzo[h]thienyl each of which is optionally substituted by one or more of the following: halo or a C₁₋₄alkyl group;

~~or L² represents a C₆₋₁₀cycloalkyl group which is fused to an R⁵ which is phenyl or a heteroaryl group selected from thienyl, furyl or pyrrolyl;~~

then R⁴ does not represent H or a C₁₋₄alkyl group; and excluding 1,4-anhydro-2,3,5-trideoxy-3-[[[(3,4-dichlorophenyl)methyl]amino]-5-[(4-ethoxy-2-quinoliny)amino]-D-erythro-pentitol.

2. (currently amended) A compound as claimed in claim 1 in which L¹ represents a monocyclic -(CH₂)_pC₅₋₆(CH₂)_q- cycloalkyl group in which p and q are independently 0 or 1 wherein there are 3 carbon atoms between the two nitrogens bearing R³ and R⁴, respectively, wherein one of the carbons of the cycloalkyl group may be replaced by O or the group -N(R³)-L¹-, or the group -L¹-N(R⁴)-, together represent a saturated heterocyclic ring containing from 4 to 6 carbon atoms and the nitrogen bearing R³ or R⁴ respectively.

3. (previously presented) A compound of formula IA



IA

in which

R^1 represents chloro, fluoro, methoxy or a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group;

n represents 0, 1 or 2 and when $n=1$ the substituent is attached to either position 6 or 7;

R^2 represents a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;


L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, 1*H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_nR^y$ in which n is 0, 1 or 2 and R^y

is phenyl optionally substituted by cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

4. (previously presented) A compound of formula IB



in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

A represents CH_2 and t is 0 or 1;


R^4 represents H;

L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl,

pyrazolyl, or quinolin-2-yl each of which is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro and in addition when R⁵ is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C₁₋₄ alkyl group optionally substituted by one or more fluoro and when R⁵ is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

5. (previously presented) A compound of formula IC



in which

R¹ represents H, methoxy, dimethylamino, chloro or fluoro;

R² represents H, a C₁₋₄alkyl group or a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R³ represents H;

A represents CH₂ and t is 0 or 1;

R⁴ represents H;

L² represents CH₂, C(CH₃)₂ or CF₂; and

R⁵ represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, 1*H*-pyrrolo[3,2-*b*]pyridinyl or quinolin-2-yl each of which is optionally substituted by

one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro and in addition when R⁵ is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C₁₋₄ alkyl group optionally substituted by one or more fluoro and when R⁵ is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

6. (original) A compound as claimed in any one of claims 1 to 5 in which p is 0, q is 0 and L¹ is 1,3-cyclohexyl.

7. (previously presented) A compound as claimed in any one of claims 1 to 5 in which the two nitrogen atoms are in a trans orientation on the cycloalkyl ring.

8. (original) A compound as claimed in claim 7 wherein the absolute configuration of the cycloalkyl carbon atoms to which the nitrogen atoms are attached is S, S.

9. (previously presented) A compound according to any one of claims 1 to 5 in which R⁵ represents one of the following:

1*H*-pyrrolo[3,2-*c*]pyridinyl;

1*H*-pyrrolo[2,3-*b*]pyridinyl;

1*H*-indazolyl;

1-imidazo[1,2-*a*]pyridinyl;

5*H*-pyrrolo[2,3-*b*]pyrazinyl;

1*H*-pyrrolo[3,2-*b*]pyridinyl;

1*H*-pyrrolo[3,2-*h*]quinolinyl;

2,1,3-benzothiadiazolyl; and

2,1,3-benzoxadiazolyl;

wherein each of these heterocycles is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group S(O)_aR^y in which a is 0, 1 or 2 and R^y

is phenyl optionally substituted by cyano, halo, a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, or by a group O_z(CH₂)_wR^z in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄alkyl group optionally substituted by one or more fluoro, or a C₁₋₄alkoxy group optionally substituted by one or more fluoro.

10. (currently amended) A compound as claimed in any one of claims 1 to 5 in which L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³)-L¹ or the group L¹-N(R⁴) together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively; with the proviso that L¹ is not 1,4-cyclohexyl or 1,3-cyclopentyl.

11. (original) One or more of the following compounds:

N,N-dimethyl-2-[(3-[(5-pyridin-2-yl-2-thienyl)methyl]amino)cyclohexyl]amino]-quinoline-4-carboxamide;

(1*S*,3*S*)-*N*-(6-chloro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*R*,3*R*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methoxyquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]cyclopentane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrol-2-yl)methyl]cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(quinolin-3-ylmethyl)cyclohexane-1,3-diamine;

*N*⁶,*N*⁶-dimethyl-*N*²-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,6-diamine;

(1*S*,3*S*)-*N*-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(1,2,3-thiadiazol-4-ylmethyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(5-pyridin-2-yl-2-thienyl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-({1-[(2-chloro-1,3-thiazol-5-yl)methyl]-1*H*-indol-3-yl}methyl)-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(2,2'-bithien-5-ylmethyl)-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,4-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-[3-({2-(phenylsulfonyl)-1,3-thiazol-5-yl}methyl)amino]cyclohexyl]quinoline-2,4-diamine;

*N*²-(3-{[(2,4-dimethoxypyrimidin-5-yl)methyl]amino}cyclohexyl)-*N*⁴,*N*⁴-dimethylquinoline-2,4-diamine;

3-(6-methoxy-4-methylquinolin-2-yl)-*N*-methyl-*N*-(3-thienylmethyl)-3-azabicyclo[3.2.1]octan-8-amine;

6-methoxy-4-methyl-*N*-[({(1*R*,2*S*)-2-{[(1-methyl-1*H*-indol-3-yl)methyl]amino}cyclopentyl)methyl]quinolin-2-amine;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-3-[(3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl)amino)methyl]-1-methyl-1*H*-indole-6-carbonitrile;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-2-

yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-({1-[3-(trifluoromethyl)pyridin-2-yl]-1*H*-indol-3-yl} methyl)cyclopentane-1,3-diamine;

(1S,3S)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indazol-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl} methyl)cyclopentane-1,3-diamine;

3-[(1S,3S)-3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl] amino)methyl]-1-methyl-1*H*-indole-5-carbonitrile;

(1S,3S)-*N*-{[5-difluoromethoxy-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1S,2S,4*R*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*R*,2*S*,4*S*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1S,2*S*,4*R*,6*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]bicyclo[2.2.1]heptane-2,6-diamine;

6-methoxy-4-methyl-*N*-[(1*S*,2*R*)-2-({(1-methyl-1*H*-indol-3-yl)methyl}amino)methyl]cyclopentyl]quinolin-2-amine;

(1S,3S)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*h*]quinolin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(imidazo[1,2-*a*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-*N*-{[5-(Benzyloxy)-1-methyl-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1S,3S)-*N*-(7-Methoxy-4-methylquinolin-2-yl)-*N'*-[3-(trifluoromethoxy)benzyl]-

cyclohexane-1,3-diamine;

(1S,3S)-N-(2,1,3-Benzothiadiazol-4-ylmethyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

(1S,3S)-N-[(1,3-Dimethyl-1H-pyrazol-4-yl)methyl]-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine; and

(1S,3S)-N-(2-Bromo-4-methoxybenzyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

and pharmaceutically acceptable salts thereof.

12. (canceled).


13. (previously presented) A pharmaceutical formulation comprising a compound as defined in any one of claims 1 to 5 or claim 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (cancelled).


15. (previously presented) A method of treating obesity, a psychiatric disorder, anxiety, an anxio-depressive disorder, depression, bipolar disorder, ADHD, a cognitive disorder, a memory disorder, schizophrenia, epilepsy, a neurological disorder and a pain related disorder, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.

16. (canceled).

17. (currently amended) A process for the preparation of a compound of formula I



comprising reacting a compound of formula II



in which

R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO₂C₁₋₄alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl $(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4 , respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group $-N(R^3)-L^1-$ or the group $-L^1-N(R^4)-$ together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively; and

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;


with a compound of formula III



III

in which R^5 is as previously defined and L^2 represents a group which after reaction of compounds II and III gives L^2 on reduction, under reductive alkylation conditions.

18. (currently amended) A compound of formula II



II

in which

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, cyano, a group $OSO_2C_{1-4}alkyl$ wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a $C_{1-4}alkyl$ group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a

C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄ alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R³ represents H or a C₁₋₄ alkyl group;

L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³)-L¹ - or the group L¹-N(R⁴)- together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively; and~~

R⁴ represents H or a C₁₋₄ alkyl group optionally substituted by one or more of the following: fluoro or C₁₋₄ alkoxy optionally substituted by one or more fluoro.

19. (previously presented) A compound selected from one or more of:

(1S, 3S)-Dibenzyl-cyclohexane-1,3-diylbiscarbamate; and

(1S, 3S)-Cyclohexane-1,3-diamine dihydrochloride.

20. (previously presented) A method of treating obesity, type II diabetes, or Metabolic syndrome comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.

21. (previously presented) A method of preventing type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.